Literature DB >> 1492615

Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases.

M Harada1, M Iida, M Yamaguchi, K Shida.   

Abstract

Metastatic frequency to various organ sites in 137 autopsy cases with histologically confirmed prostatic adenocarcinoma was examined retrospectively. Bone lymph node metastases were observed in 81% and 82.5% of the cases, respectively. Lung and liver metastases were noted in 46.7% and 30.7% of the cases respectively. Statistical analysis of the inter-relation among metastases to the bones, lymph nodes, lungs and liver revealed that 83.2% of cases with lymph node metastasis also had bone metastasis. Sixty out of 64 cases with lung metastasis also presented with bone metastasis. There was a significant correlation of metastases between bones and lymph nodes, bones and lungs, and lymph nodes and lungs. Although approximately 88% of cases with liver metastasis also had bone metastasis, this relationship was not statistically significant. there was a statistically significant relationship between lung metastasis and specific sites of bone metastases, i.e. vertebrae, ribs, and sternum. Using the Cochran-Mantel-Haenszel statistical method, we found that the metastatic combination between lung and bone was significantly related in cases with or without lymph node metastasis. These observations suggest that the Batson's vertebral system might play an important role in the metastatic spread of prostatic adenocarcinoma either to the bones or lungs.

Entities:  

Mesh:

Year:  1992        PMID: 1492615     DOI: 10.1007/978-1-4615-3398-6_18

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

Review 1.  Prostate cancer: a comprehensive review.

Authors:  S N Pentyala; J Lee; K Hsieh; W C Waltzer; A Trocchia; L Musacchia; M J Rebecchi; S A Khan
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

2.  PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy?

Authors:  Raymond Miralbell; Franz Buchegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07       Impact factor: 9.236

3.  Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.

Authors:  Hung-Ming Lam; Holly M Nguyen; Eva Corey
Journal:  Methods Mol Biol       Date:  2018

4.  Prostate cancer cell surface-associated keratin 8 and its implications for enhanced plasmin activity.

Authors:  Melissa Hirsch Kuchma; Joo Hee Kim; Mark T Muller; Philip A Arlen
Journal:  Protein J       Date:  2012-03       Impact factor: 2.371

Review 5.  Osteoclast-targeted therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Curr Treat Options Oncol       Date:  2004-10

6.  Zoledronic acid in the management of metastatic bone disease.

Authors:  Thomas J Polascik; Vladimir Mouraviev
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

7.  Components of cell-matrix linkage as potential new markers for prostate cancer.

Authors:  Alexey Navdaev; Johannes A Eble
Journal:  Cancers (Basel)       Date:  2011-02-25       Impact factor: 6.639

8.  Induction of integrin α2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture.

Authors:  Shabnam Ziaee; Leland W K Chung
Journal:  Mol Cancer       Date:  2014-09-08       Impact factor: 27.401

Review 9.  Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics.

Authors:  Shabnam Ziaee; Gina Chia-Yi Chu; Jen-Ming Huang; Shirly Sieh; Leland W K Chung
Journal:  Transl Androl Urol       Date:  2015-08

10.  The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer.

Authors:  Ciro Franzese; Paolo Andrea Zucali; Lucia Di Brina; Giuseppe D'Agostino; Pierina Navarria; Davide Franceschini; Armando Santoro; Marta Scorsetti
Journal:  Cancer Med       Date:  2018-08-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.